Zepbound beats Wegovy for weight loss
Digest more
Hosted on MSN2d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders WaryEli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine and presented at the European Congress on Obesity.
(RTTNews) - Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during ...
President Trump announced an executive order to significantly reduce U.S. drug prices, aiming to align with costs in other nations. Eli Lilly's Zepbound drug outperforms Wegovy in a weight-loss trial.